The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis

Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market.

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
WWW.ROOTSANALYSIS.COM
CAR-T Therapies Market (3rd Edition) | Industry Analysis | Market Size | 2030
CAR-T Therapies market report features an extensive study of the current market landscape and future potential of the industry players
0 Comments 0 Shares